Argus Research Maintains Buy on GlaxoSmithKline, Raises Price Target to $50

Argus Research maintains GlaxoSmithKline (NYSE:GSK) with a Buy and raises the price target from $47 to $50.

Benzinga · 11/11/2019 14:29

Argus Research maintains GlaxoSmithKline (NYSE:GSK) with a Buy and raises the price target from $47 to $50.